| Income Statement | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,464,655 | 3,091,390.5* | 1,899,251 | 1,226,954 |
| General and administrative | 1,326,891 | 2,193,765.5* | 1,576,577 | 1,540,910 |
| Total operating expenses | 2,791,546 | 5,285,156 | 3,475,828 | 2,767,864 |
| Loss from operations | -2,791,546 | -5,285,156* | -3,475,828 | -2,767,864 |
| Investment income, net | 32,518 | 44,652.5 | 46,704 | 27,305 |
| Interest expense | 77,273 | - | - | - |
| Change in fair value of derivative liability | 22,187 | - | - | - |
| Total other income (expense), net | -22,568 | 44,652.5* | 46,704 | 27,305 |
| Net loss | -2,814,114 | -5,240,503.5 | -3,429,124 | -2,740,559 |
| Deemed dividend series a preferred stock | 18,052 | - | - | - |
| Net loss available to common share available to common shareholders | -2,832,166 | - | - | - |
| Basic EPS | -0.54 | -2.468 | -1.16 | -2.15 |
| Diluted EPS | -0.54 | -2.468 | -1.16 | -2.15 |
| Basic Average Shares | 5,232,625 | 2,123,344* | 2,943,655 | 1,277,217 |
| Diluted Average Shares | 5,232,625 | 2,123,344* | 2,943,655 | 1,277,217 |
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)